SLC5A2 and chronic kidney disease: The ESC guidelines for treatment of persons with T2D and CKD recommend sequentially initiating and titrating doses of an ACEi or ARB, an SGLT2 inhibitor, finerenone, and a GLP‐1 RA in addition to BP control and a statin‐based regimen to reduce the risk of CVD and kidney failure [44].